Form D · Other
NovaBay Pharmaceuticals, Inc.
Emeryville, CA · CIK 0001389545
Offering snapshot reported Jan 27, 2026 · SEC filing
- Reported sold
- $134M Offering amount: $134M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Jan 16, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 27, 2026 | Initial | $134,000,000 | No comparison | 4 | SEC filing |
| Jun 28, 2024 | Initial | $225,953 | No comparison | 5 | SEC filing |
| Apr 5, 2024 | Initial | $665,000 | No comparison | 5 | SEC filing |
| Jan 4, 2024 | Initial | $554,808 | No comparison | 5 | SEC filing |
| May 18, 2023 | Initial | $3,000,000 | No comparison | 5 | SEC filing |
| Sep 23, 2022 | Initial | $2,065,500 | No comparison | 9 | SEC filing |
| Sep 23, 2022 | Initial | Yet to sell | No comparison | 4 | SEC filing |
| Nov 17, 2021 | Initial | $15,000,000 | No comparison | 7 | SEC filing |
| Jul 31, 2020 | Initial | $0 | No comparison | 0 | SEC filing |
| May 22, 2020 | Initial | $1,030 | No comparison | 0 | SEC filing |
| May 1, 2020 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Aug 26, 2019 | Initial | $4,198,566 | No comparison | 4 | SEC filing |
| Aug 26, 2019 | Initial | $2,700,000 | No comparison | 3 | SEC filing |
| Jul 3, 2019 | Initial | $2,400,000 | No comparison | 3 | SEC filing |
| Feb 14, 2018 | Initial | $5,984,000 | No comparison | 1 | SEC filing |
| May 20, 2016 | Initial | $7,791,000 | No comparison | 9 | SEC filing |
| Feb 26, 2016 | Initial | $2,830,804 | No comparison | 3 | SEC filing |
| Jun 4, 2015 | Amendment | $26,582,871 | $11,448,571vs Mar 19, 2015 | 21 | SEC filing |
| Mar 19, 2015 | Initial | $15,134,300 | No comparison | 14 | SEC filing |
| Apr 3, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-571260
Source: Form D, filed Jan 27, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Charles Cashion | Director |
| Lynn Christopher | Executive |
| Paul Freiman | Director |
| Julie Garlikov | Director |
| Justin Hall | Director, Executive |
| Andrew Jones | Executive |
| Michael John Kazley | Director, Executive |
| Audrey Kunin | Director, Executive |
| Jeffrey Kunin | Executive |
| Tommy Law | Executive |
| Xinzhou (Paul) Li | Director |
| Xiaoyan (Henry) Liu | Director |
| Xiaoyan Liu | Director |
| Yonghao (Carl) Ma | Director |
| Gail Maderis | Director |
| John J. Mc Govern | Executive |
| T. Alex Mc Pherson | Director |
| T. Alex Mc Pherson | Director |
| Ramin (Ron) Najafi | Director, Executive |
| Thomas J. Paulson | Executive |
| Massimo Radaelli | Director |
| Jason Raleigh | Executive |
| Mark Sieczkarek | Director |
| Swan Sit | Director |
| Lewis J. Stuart | Executive |
| Xiaopei (Ray) Wang | Director |
| Tony Wicks | Director |
| Mijia Wu | Director |
| Mijia (Bob) Wu | Director |
| Roy J. Wu | Executive |
| Todd Zavodnick | Director |
| Yongxiang (Sean) Zheng | Director |
| Yenyou (Jeff) Zheng | Director |
Issuer details
Industry: Other (See others in industry)
Address:
2000 Powell Street, Suite 1150
Emeryville, CA, 94608
Emeryville, CA, 94608